Saili Medical: Ethical approval obtained for the treatment of hypertension vaccine HJY-ATRQ-001 injection.

Recently, an I-phase clinical trial project led by Hua Jiyuan Biology, a subsidiary of Sceli Medical Strategic Holdings, and carried out by Stand Medical as a CRO, has officially received approval from the Medical Ethics Committee of Tongji Medical College Affiliated Union Hospital of Huazhong University of Science and Technology. This marks a solid and crucial first step in the road to human clinical trials for the innovative drug "HJY-ATRQ-001 Injection" invested by Sceli Medical.